Abstract
AbstractIdentifying high-affinity antibodies in human serum is challenging due to extremely low number of circulating B cells specific to the desired antigens. Delays caused by a lack of information on the immunogenic proteins of viral origin hamper the development of therapeutic antibodies. We propose an efficient approach allowing for enrichment of high-affinity antibodies against pathogen proteins with simultaneous epitope mapping, even in the absence of structural information about the pathogenic immunogens. To screen therapeutic antibodies from blood of recovered donors, only pathogen transcriptome is required to design an antigen polypeptide library, representing pathogen proteins, exposed on the bacteriophage surface. We developed a two-dimensional screening approach enriching lentiviral immunoglobulin libraries from the convalescent or vaccinated donors against bacteriophage library expressing the overlapping set of polypeptides covering the spike protein of SARS-CoV-2. This platform is suitable for pathogen-specific immunoglobulin enrichment and allows high-throughput selection of therapeutic human antibodies.
Funder
Russian Science Foundation
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Aleem, A. & Vaqar, S. Monoclonal antibody therapy for high-risk coronavirus (COVID 19) patients with mild to moderate disease presentations. in StatPearls (StatPearls Publishing, 2023).
2. Teng, I.-T. et al. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. PLoS ONE 17, e0268767 (2022).
3. Zhou, T. et al. Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 Spike molecular probes. Cell Rep. 33, 108322 (2020).
4. Liu, C. et al. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell Host Microbe 30, 53–68.e12 (2022).
5. Takeshita, M. et al. Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents. iScience 26, 106955 (2023).